Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
2015

Evaluation of α,β-unsaturated
, -unsaturated ketones as antileishmanial agents
Miguel A. Vasquez
University of Texas at El Paso

Eva Iniguez
University of Texas at El Paso

Umashankar Das
University of Saskatchewan

Stephen M. Beverley
Washington University School of Medicine in St. Louis

Linda J. Herrera
University of Texas at El Paso

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
Vasquez, Miguel A.; Iniguez, Eva; Das, Umashankar; Beverley, Stephen M.; Herrera, Linda J.; Dimmock,
Jonathan R.; and Maldonado, Rosa A., ,"Evaluation of α,β-unsaturated ketones as antileishmanial agents."
Antimicrobial agents and chemotherapy. 59,. 3598-3601. (2015).
https://digitalcommons.wustl.edu/open_access_pubs/3929

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been
accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker.
For more information, please contact vanam@wustl.edu.

Authors
Miguel A. Vasquez, Eva Iniguez, Umashankar Das, Stephen M. Beverley, Linda J. Herrera, Jonathan R.
Dimmock, and Rosa A. Maldonado

This open access publication is available at Digital Commons@Becker: https://digitalcommons.wustl.edu/
open_access_pubs/3929

Evaluation of ␣,␤-Unsaturated Ketones as Antileishmanial Agents
Miguel A. Vasquez,a Eva Iniguez,a Umashankar Das,b Stephen M. Beverley,c Linda J. Herrera,a Jonathan R. Dimmock,b
Rosa A. Maldonadoa

In this study, we assessed the antileishmanial activity of 126 ␣,␤-unsaturated ketones. The compounds NC901, NC884, and
NC2459 showed high leishmanicidal activity for both the extracellular (50% effective concentration [EC50], 456 nM, 1,122 nM,
and 20 nM, respectively) and intracellular (EC50, 1,870 nM, 937 nM, and 625 nM, respectively) forms of Leishmania major propagated in macrophages, with little or no toxicity to mammalian cells. Bioluminescent imaging of parasite replication showed that
all three compounds reduced the parasite burden in the murine model, with no apparent toxicity.

L

eishmania major is the causative agent of cutaneous leishmaniasis (CL) disease (1). Worldwide, the incidence of CL is estimated to be 0.7 to 1.2 million new cases per year (2). Other than
the drug miltefosine, which was approved by the FDA in 2014,
most of the currently used antileishmanial drugs were developed
in the 1940s (3, 4). However, drug-resistant strains of the parasite
have emerged. Furthermore, toxicity to the host and the high costs
of these drugs limit their wider application and use (4, 5). Therefore, the burden of leishmaniasis and limited effective treatments
clearly point to the need for new drugs.
In view of the current interest in examining different antineoplastic agents for their antiprotozoal properties (6–8), we assessed
the antileishmanial activity of ␣,␤-unsaturated ketones (enones)
provided by J. R. Dimmock from the University of Saskatchewan
in Canada (1, 9). Enones react preferentially with cellular thiols, in
contrast to amino or hydroxyl functional groups present in protein and DNA (10, 11); therefore, interactions with nucleic acids,
which can lead to adverse genotoxic effects, should be absent in
enones (12). Since thiol-dependent metabolism is the main detoxifying mechanism in trypanosomatids, we hypothesized that
enones are attractive candidates for examination as potential
antileishmanial agents.
Hence, in this study, we screened the enone library for antiparasitic and cytotoxic activity. The compounds were dissolved in
dimethyl sulfoxide (DMSO) and tested at concentrations ranging
from 500 M to 1 nM (1, 9). The parasites tested were a firefly
luciferase-expressing line of L. major promastigotes described previously (Lmj-FV1-LUC-TK [L. major strain Friedlin {MHOM/JL/
80/Friedlin}], clone V1) and cultured as previously described (13,
14). The 126 enones were incubated with 106 L. major promastigotes or rhesus monkey kidney epithelial cells (LLC-MK2)/well for
96 h and were analyzed for toxicity and parasite survival as measured by luciferase activity with the substrate 5=-fluoroluciferin
(ONE-Glo luciferase assay system; Promega) using a luminometer
(Luminoskan; Thermo Scientific). Sixty-four compounds inhibited the survival of L. major promastigotes at ⬎75%. At the same
concentrations tested, 20 out of 126 screened compounds displayed minimal to no toxicity (⬎75% survival) against LLC-MK2
cells. Only six compounds met the criteria for both antiparasitic
activity (⬍25%) and low cytotoxicity to LLC-MK2 cells (⬎75%)
(see Fig. S1 in the supplemental material). These six compounds
were further tested in the following mammalian cell lines: Hs27
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human fibroblasts, RAW 264.7 murine macrophages (American
Type Culture Collection [ATCC], Manassas, VA), and peritoneal
BALB/c mice macrophages, obtained as described previously (15).
Only NC901, NC884, and NC2459 showed effective activity
against L. major. NC2459 showed a 100-fold difference between
the 50% effective concentration (EC50) of the parasite and that for
all three mammalian cell lines (Table 1).
The in vitro infectivity experiments were carried out to determine the activity of NC901, NC884, and NC2459 against L. major
intracellular amastigotes. Peritoneal macrophages isolated from
BALB/c mice were infected with L. major metacyclic promastigotes for 24 h, followed by treatment with the NC lead compounds
for an additional 48 h (Table 1). The antileishmanial activity exhibited by the compounds was evaluated using BD Pathway Bioimager high-content imaging assay (HCIA) analysis (16–18). In
comparison to the 1% DMSO control, all three compounds
showed a significant decrease in the percentage of infected cells.
NC2459 was the most effective at a concentration of 1.25 M
(Table 1).
Additionally, the activity of the compounds against L. major
was investigated in a murine model of CL. The first set of experiments (Fig. 1A) consisted of 12 female BALB/c mice organized in
four groups of three, each infected with 105 L. major metacyclic
promastigotes (Table 2). As shown in Fig. 1A, at 46 days postinfection, all experimental groups exhibited a lesion size smaller
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TABLE 1 Summary of EC50 and IC50 for NC901, NC884, and NC2459 tested against L. major and mammalian cellsa
Mammalian cell EC50 (M) ⫾ SD for:
Compound

L. major cells (M) (TI)

LLC-MK2

Hs27 fibroblasts

Promastigote EC50

Intracellular
amastigote IC50

7.03 ⫾ 0.42

8.02 ⫾ 0.25

16.0 ⫾ 0.12

0.45 (15.62)

1.87 ⫾ 0.20 (3.76)

7.67 ⫾ 0.31

15.1 ⫾ 0.33

16.3 ⫾ 0.17

1.12 (6.55)

0.937 ⫾ 0.13 (8.18)

5.45 ⫾ 0.36

2.0 ⫾ 0.093

10.01 ⫾ 0.09

0.020 (272.5)

0.625 ⫾ 0.11 (8.72)

a

EC50, half-maximal effective concentration calculated with 95% confidence; IC50, 50% inhibitory concentration; TI, therapeutic index, calculated as (EC50 peritoneal murine
macrophages)/(EC50/IC50 parasites). The EC50 was obtained as the exponent of the negative ratio of the y-intercept and the slope of the fitted regression line (version 9.2; SAS
Software). P value, ⬍0.0001 for all concentrations. The Z-factor calculated for the HCIA is in the range of 0.5 to 0.91, indicating that the quality of the assay is excellent.

than or equal to that of the group treated with amphotericin B.
Further support was obtained by determining the relative amount
of luminescence emitted from the luciferase-expressing parasites
in the infected footpad at the endpoint of the study, namely, 46
days postinfection (Fig. 1C). All mice in the NC2459 group did not
develop measurable lesions until 2 to 3 weeks after the last treatment (total of 6 to 7 weeks postinfection). Furthermore, one out
of the three mice did not develop a lesion up to 12 weeks postinfection.
To determine the relative toxicity of the compounds, the
weights of the mice were measured twice a week (data not shown).
There was no significant weight loss for any of the groups except
for the mice receiving amphotericin B. Additionally, no mice died
as a result of the toxicity of the compounds.
Hyperinfection with L. major was tested. Twenty-six female
BALB/c mice organized in four groups of five and one group of six
mice were infected with 106 L. major metacyclic promastigotes
(Fig. 1B). All experimental groups were given higher doses than
the groups receiving 105 L. major metacyclic promastigotes (Table
2). At 4 weeks postinfection, the lesion size in all three NC compounds significantly reduced in comparison to that of the diluent
control group (P ⱕ 0.05). However, at 29 days postinfection, the
mice in the diluent control group had to be euthanized to avoid
physical distress caused by a large lesion; all other groups were
monitored for an additional 4 days. For this reason, the luminescence from the infected footpads for each group was analyzed at 29
days postinfection and not at the endpoint of the experiment (Fig.
1D). After 1 week of treatment with NC2459, three of the mice
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from this group were given double the daily dose of drug (8 mg/kg
of body weight/day), while the other three remained on the same
daily dose (4 mg/kg/day). In addition, the three mice given the
higher dose were treated with four additional doses. Those given
NC2459 (extended treatment) at 33 days postinfection showed a
smaller lesion than that of all the other groups (P ⱕ 0.05). The
increase in dosage for NC2459 (extended treatment) did not result
in any additional weight loss or toxic side effects in comparison to
those of the control group. The procedures were performed to
minimize distress and pain for the animals according to NIH
guidance and the animal protocol approved by The University of
Texas at El Paso (UTEP) Institutional Animal Care and Use Committee (IACUC).
Our findings demonstrate the ability of these compounds to
reduce L. major replication in vivo without any obvious toxic side
effects. NC2459 evidently exhibited a much smaller amount of
swelling than that in all other groups by decreasing the footpad
lesion by 99.99% (Fig. 1A) in comparison with that of the diluenttreated group. In summary, the data obtained in this study suggest
that our lead compound, NC2459, is an excellent antiparasitic
agent and might be useful as a potential alternative to the current
clinical drugs used to treat leishmaniasis. Clearly, NC2459 is an
important lead molecule, which is structurally divergent from
contemporary medications employed to treat parasitic diseases. It
is a prototypic molecule, and further molecular modifications are
required, followed by the relevant bioassays, to increase potency
and especially to increase the differential in toxicities between parasites and normal cells.
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Peritoneal murine
macrophages
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L. major metacyclic promastigotes, respectively. The Rx1 line refers to the time period in which treatment was administered daily, and the Rx2 line indicates that
the daily dosage of NC2459 was doubled for that time period. (C) Luminescence of BALB/c mice footpads at 46 days postinfection with 105 metacyclic
promastigotes. *, P ⬍ 0.05. (D) Luminescence of BALB/c mice footpads at 29 days postinfection with 106 metacyclic promastigotes. C, group treated with vehicle
control; CD, group treated with amphotericin B. A statistical analysis of the net intensity (luminescence) of both the 105 and 106 experiments was carried out
using the two-sided unpaired t test. *, P ⱕ 0.05; **, P ⱕ 0.01.
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Treatment (mg/kg/day) after infection with:
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105 promastigotesa

106 promastigotesb

DMSO (100 l)
AmpBc
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NC884
NC2459

8
2
4
1

8
4
8
4 (3 mice/14 days)/
8 (3 mice/days 8–17)

a

The mice infected with 105 L. major metacyclic promastigotes were treated for 14
consecutive days at the stated dosages.
b
The mice infected with 106 L. major metacyclic promastigotes (hyperinfection
experiment) were split into two groups of three mice after 7 days of treatment with
NC2459. One group remained on the same treatment, 4 mg/kg/day, for seven more
days (14 total days of treatment), and the other group was given double the daily
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c
AmpB, amphotericin B.
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